Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 210 mg brodalumab Clear all
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708629
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 3, 2026, 1:20 AM EDT
Not listed Phase 2 Interventional

Treatment of Moderate Hidradenitis Suppurativa

NCT03910803
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Brodalumab
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 3, 2026, 1:20 AM EDT
Completed Phase 4 Interventional Results available

Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

NCT03403036
View directory record Official record
Conditions
Psoriasis
Interventions
Brodalumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 3, 2026, 1:20 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

NCT01101100
View directory record Official record
Conditions
Psoriasis
Interventions
AMG 827
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Newnan, Georgia • Skokie, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 3, 2026, 1:20 AM EDT
Recruiting Phase 1 Interventional

Brodalumab in the Treatment of Immune-Related Adverse Events

NCT06673329
View directory record Official record
Conditions
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions
Brodalumab, CT scan
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 3, 2026, 1:20 AM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

NCT02029495
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
210 mg brodalumab, 140 mg brodalumab, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
43
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 3, 2026, 1:20 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of AMG 827 in Subjects With RA

NCT01059448
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AMG 827
Drug
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 3, 2026, 1:20 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

NCT02024646
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
210 mg brodalumab, 140 mg brodalumab, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Peoria, Arizona • Little Rock, Arkansas • Cypress, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 3, 2026, 1:20 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708590
View directory record Official record
Conditions
Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Bakersfield, California • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 3, 2026, 1:20 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

NCT01902290
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Brodalumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 3, 2026, 1:20 AM EDT
Terminated Phase 3 Interventional Results available

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 3, 2026, 1:20 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

NCT01199289
View directory record Official record
Conditions
Asthma
Interventions
AMG 827, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 3, 2026, 1:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab

NCT02173392
View directory record Official record
Conditions
Psoriasis
Interventions
Brodalumab
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
6
States / cities
Glendale, California • Aventura, Florida • Saint Paul, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 3, 2026, 1:20 AM EDT
Terminated Phase 2 Interventional Results available

Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

NCT01150890
View directory record Official record
Conditions
Crohn's Disease
Interventions
Brodalumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Dothan, Alabama • Lowell, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Sep 3, 2026, 1:20 AM EDT
Withdrawn Phase 2 Interventional

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

NCT02429882
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Brodalumab 210 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Oklahoma City, Oklahoma • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Sep 3, 2026, 1:20 AM EDT